How does Peptisoothe Oral Liquid Syrup (Ranitidine HCL) work:

Peptisoothe Oral Liquid Syrup (Ranitidine HCL) is indicated for the treatment of duodenal ulcer including that associated with non-steroidal anti-inflammatory agents and the prevention of non-steroidal anti-inflammatory agent (including aspirin) associated duodenal ulcers in patients with a history of duodenal ulceration proven by endoscopy.

Peptisoothe is also used in the treatment of post-operative ulcer, oesophageal reflux disease, Zollinger-Ellison syndrome, chronic episodic dyspepsia, etc.

The active ingredient of Peptisoothe, Ranitidine, is a rapidly acting histamine H2-antagonist. Ranitidine works by inhibiting basal and stimulated secretion of gastric acid, reducing both the volume and the acid and pepsin content of the secretion. Ranitidine has a relatively long duration of action and so a single 150mg dose effectively suppresses gastric acid secretion for 12 hours.

Dosage & Administration:

- Adults:

Duodenal Ulcer and Benign Gastric Ulcer:
The usual dosage is 150mg twice a day, taken in the morning and evening. Patients with duodenal or gastric ulceration may be treated with a single bedtime dose of 300mg.

NSAID Associated Peptic Ulceration:
The treatment may be necessary with 150mg twice a day (or 300mg at bedtime) for 8-12 weeks.

Postoperative Ulcer:
The dosage is 150mg twice a day. Most cases heal within 4 weeks. Those not fully healed after the initial 4 weeks usually do so after a further 4 weeks.

Gastro-Oesophageal Reflux Disease:
The recommended course of treatment is either 150mg twice a day (or 300mg at bedtime) for up to 8 weeks.
* In patients with severe oesophageal reflux disease, the dosage may be increased to 150mg four times a day for up to 12 weeks.

Zollinger-Ellison Syndrome:
The starting dose is 150mg three times a day (may be increased as necessary).

Chronic Episodic Dyspepsia:
The recommended course of treatment is 150mg twice a day for up to 6 weeks.

Prophylaxis of Mendelson`s Syndrome:
An oral dose of 150mg can be given 2 hours before induction of general anaesthesia, and preferably also 150mg orally the previous evening.

Prophylaxis of Haemorrhage from Stress Ulceration or from Peptic Ulceration:
Treatment with 150mg syrup twice daily may be substituted for injection once oral feeding commences in patients considered to be still at risk from these conditions.

- Children:

Use with Peptisoothe (Ranitidine) in children has not been fully evaluated in clinical studies. However, it has been used successfully in children aged 8-18 years in doses up to 150mg twice a day.

Side Effects:

• blood count changes
• agranulocytosis
• pancytopenia
• marrow hypoplasia or aplasia
• bradycardia
• vasculitis
• blurred vision
• diarrhoea
• hepatitis
• arthralgia
• myalgia
• dizziness
• mental confusion
• depression
• hallucinations
• involuntary movement disorders
• erythema multiforme
• alopecia
• urticaria
• angioneurotic oedema
• fever
• bronchospasm
• hypotension
• anaphylactic shock
• chest pain
• acute interstitial nephritis

Precautions:

The possibility of malignancy should be excluded before commencement of therapy in patients with gastric ulcer as treatment with Peptisoothe may mask symptoms of gastric carcinoma.

Peptisoothe is excreted via the kidney and so plasma levels of the drug are increased in patients with severe renal impairment.

Regular supervision of patients who are taking non-steroidal anti-inflammatory drugs concomitantly with Peptisoothe is recommended, especially in the elderly and in those with a history of peptic ulcer.